Oral Contraceptive Pills May Increase Binge Eating Risk in Women

A new study published in Psychoneuroendocrinology on June 15, 2026, found that women using combined oral contraceptives containing both estrogen and progestin may experience a statistically significant increase in binge eating behaviors, according to researchers at the University of California, San Francisco (UCSF). The findings, drawn from a longitudinal analysis of 1,200 women aged 18–35, suggest a link between hormonal contraception and disordered eating patterns in a subset of users, though the biological mechanisms remain under investigation.

The study’s lead author, Dr. Elena Martinez, an associate professor of psychiatry at UCSF, emphasized that the effect was not universal: “About 15% of participants reported a noticeable increase in binge eating episodes after starting or switching to combined oral contraceptives, compared to a 5% baseline rate in the control group.” The increase was most pronounced among women with a prior history of emotional eating or mild binge-eating disorder, though the researchers stressed that correlation does not prove causation.

This research builds on earlier observational studies, including a 2022 paper in JAMA Psychiatry that linked hormonal fluctuations to appetite dysregulation in some women. However, the UCSF study is among the first to isolate the specific role of estrogen-progestin combinations, distinct from progestin-only pills, which showed no significant association with binge eating in the dataset. The distinction is critical: combined pills remain the most widely prescribed form of birth control globally, with over 100 million users worldwide.

Why the difference? Hormonal contraceptives suppress natural estrogen and progesterone cycles, which some research suggests may alter serotonin and dopamine pathways linked to impulse control and reward-seeking behaviors. “Estrogen has a modulatory effect on serotonin receptors in the brain,” explained Dr. Martinez. “When exogenous estrogen is introduced at synthetic levels, it could theoretically disrupt that balance in susceptible individuals.” The study did not examine whether the effect persisted after discontinuing contraceptive use, leaving a gap for future research.

The findings come as public health guidelines on contraceptive use have increasingly emphasized personalized approaches. The World Health Organization’s 2025 Medical Eligibility Criteria for Contraceptive Use already notes that women with a history of eating disorders should discuss risks and benefits with their providers—but the new data may prompt broader conversations. “This isn’t a call to abandon oral contraceptives,” said Dr. Sarah Kowalski, a reproductive endocrinologist at Mayo Clinic who reviewed the study. “But it does underscore the need for shared decision-making, especially for women who are already vulnerable to disordered eating.”

Not all experts agree on the clinical significance. Dr. Michael Ross, a psychiatrist at Harvard Medical School, pointed to limitations in the study’s design: “The self-reported nature of binge-eating data introduces bias, and the study didn’t account for confounding factors like stress or dieting behaviors during the observation period.” He noted that larger, randomized trials are needed before altering clinical recommendations. Meanwhile, the American College of Obstetricians and Gynecologists (ACOG) has not updated its guidance pending further validation.

For women considering oral contraceptives, the study highlights the importance of monitoring emotional and behavioral changes. The UCSF team recommended tracking appetite patterns and discussing alternatives—such as non-hormonal IUDs or progestin-only pills—with a healthcare provider if binge eating emerges. “This isn’t about blame or stigma,” said Dr. Martinez. “It’s about recognizing that hormones, even in contraceptives, can interact with our brains in ways we’re still learning to understand.”

The research was funded by the National Institute of Mental Health and published under an open-access license, allowing immediate access for clinicians and patients. A follow-up study is planned to explore whether the effect varies by pill formulation or dosage.

For readers seeking additional context, the UCSF team has compiled a detailed FAQ addressing common questions about the study’s implications, available on the university’s website.